2018
Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis
Kloprogge F, Workman L, Borrmann S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Hietala S, Aweeka F, Parikh S, Mwai L, Davis TME, Karunajeewa H, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux S, Price RN, Karbwang J, Ezzet F, Bakshi R, Stepniewska K, White NJ, Guerin PJ, Barnes KI, Tarning J. Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLOS Medicine 2018, 15: e1002579. PMID: 29894518, PMCID: PMC5997317, DOI: 10.1371/journal.pmed.1002579.Peer-Reviewed Original ResearchMeSH KeywordsAntimalarialsArtemether, Lumefantrine Drug CombinationChild, PreschoolDose-Response Relationship, DrugEthanolaminesFemaleFluorenesHumansInfantInfant, NewbornMalaria, FalciparumMaleModels, ChemicalPregnancyConceptsPregnant womenArtemether-lumefantrineCure rateClinical studiesYoung childrenCurrent standard treatment regimenUncomplicated Plasmodium falciparum malariaPharmacokinetic modelAbsorption of lumefantrinePre-treatment parasitaemiaVenous plasma dataAlternative dosing regimensPlasmodium falciparum malariaStandard treatment regimenProspective clinical studyNon-pregnant adultsLow cure ratePopulation pharmacokinetic modelRelevant clinical studiesUseful therapeutic lifeFrequency of dosingConcentration-time dataHigher individual dosesLumefantrine exposureLumefantrine levels
2007
Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa
Parikh S, Ouedraogo J, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa. Clinical Pharmacology & Therapeutics 2007, 82: 197-203. PMID: 17361129, DOI: 10.1038/sj.clpt.6100122.Peer-Reviewed Original ResearchMeSH KeywordsAlkynesAmodiaquineAntimalarialsAryl Hydrocarbon HydroxylasesBenzoxazinesBurkina FasoChromatography, High Pressure LiquidCyclopropanesCytochrome P-450 CYP2C8Dose-Response Relationship, DrugDrug InteractionsEnzyme InhibitorsGenotypeHIV Protease InhibitorsHumansLopinavirMalaria, FalciparumModels, BiologicalPolymorphism, GeneticPyridinesPyrimidinonesPyronesReverse Transcriptase InhibitorsSaquinavirSpectrophotometry, UltravioletSulfonamidesTreatment OutcomeTrimethoprimConceptsAntimalarial drug amodiaquineMalaria-infected patientsAntiretroviral drug efavirenzImportant clinical implicationsAmodiaquine metabolismCYP2C8 genotypeMalaria treatmentN-desethylamodiaquineCYP2C8 variantsCYP2C8 activityCYP2C8 inhibitorsDrug interactionsDefective metabolismClinical implicationsCYP2C8Common polymorphismsDrug efavirenzMetabolismRelevant concentrationsDrugsEfficacyPrimary metabolitesAllele frequenciesToxicitySample size